Sept 5 (Reuters) - Vaxcyte ( PCVX ), a clinical-stage

vaccine developer, will raise $1.3 billion in gross proceeds by

selling common stock and warrants, it said late on Wednesday, a

day after its shares surged to a record high on promising

results in a vaccine trial.

The company said it would sell 10.2 million shares at $103

each and warrants to buy another 2.4 million shares at $102.999

per warrant.

The prices are a roughly 5.6% discount to the stock's close

of $109.15 on Wednesday, when it dipped about 1%.

A day earlier, its shares surged as much as 48% to a record

high after Vaxcyte ( PCVX ) said its experimental pneumococcal vaccine

showed promising results in an early-stage study, with a safety

profile similar to Pfizer's ( PFE ) Prevnar 20 shot.

Vaxcyte ( PCVX ), which does not have any approved product on the

market, is working to develop vaccines to prevent or treat a

broad range of bacterial infectious diseases.

The company said the stock-and-warrant offering is expected

to close on Thursday, Sept 6.

BofA Securities, Jefferies, Leerink Partners, Goldman Sachs,

Evercore ISI, Guggenheim Securities and Mizuho are the joint

book-runners for the offering.